|
Discovery of Pyrazolopyridine Analogs as Broad-Spectrum Antivirals against Non-Polio Enteroviruses including EV-D68, EVÂA71, and CVB3
This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EVA71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some...
Published: 1/10/2024
|
Inventor(s): Jun Wang, Naoya Kitamura
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
PLpro Inhibitors Against SARS-CoV-2
There are two cysteine proteases that are encoded by SARS-CoV-2, the main protease (Mpro) and the papain-like protease (PLpro). Both of these proteases have been shown to be essential in viral replication and are validated antiviral drug targets. PLpro cleaves the viral SARS-CoV-2 polyprotein at three sites. In addition, it modulates host immune response...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Chunlong Ma, Naoya Kitamura, Yanmei Hu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules
|
|
Discovery of Non-Covalent Inhibitors Targeting the SARS-CoV-2 Main Protease
This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of more antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are non-covalent inhibitors with high...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Naoya Kitamura, Chunlong Ma
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
